Beam Therapeutics BEAM Stock
Beam Therapeutics Price Chart
Beam Therapeutics BEAM Financial and Trading Overview
Beam Therapeutics stock price | 15.27 USD |
Previous Close | 33.78 USD |
Open | 33.42 USD |
Bid | 0 USD x 2200 |
Ask | 0 USD x 800 |
Day's Range | 33.24 - 34.21 USD |
52 Week Range | 28.62 - 73.27 USD |
Volume | 722.46K USD |
Avg. Volume | 861.73K USD |
Market Cap | 2.59B USD |
Beta (5Y Monthly) | 1.626695 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.58 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 67 USD |
BEAM Valuation Measures
Enterprise Value | 1.62B USD |
Trailing P/E | N/A |
Forward P/E | -5.733558 |
PEG Ratio (5 yr expected) | -1.46 |
Price/Sales (ttm) | 33.787876 |
Price/Book (mrq) | 3.2230544 |
Enterprise Value/Revenue | 21.098 |
Enterprise Value/EBITDA | -4.681 |
Trading Information
Beam Therapeutics Stock Price History
Beta (5Y Monthly) | 1.626695 |
52-Week Change | -4.94% |
S&P500 52-Week Change | 20.43% |
52 Week High | 73.27 USD |
52 Week Low | 28.62 USD |
50-Day Moving Average | 32.55 USD |
200-Day Moving Average | 40.88 USD |
BEAM Share Statistics
Avg. Volume (3 month) | 861.73K USD |
Avg. Daily Volume (10-Days) | 687.48K USD |
Shares Outstanding | 76.22M |
Float | 63.12M |
Short Ratio | 14.23 |
% Held by Insiders | 1.90% |
% Held by Institutions | 85.43% |
Shares Short | 12.51M |
Short % of Float | 21.20% |
Short % of Shares Outstanding | 16.42% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -470.92% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -16.20% |
Return on Equity (ttm) | -36.14% |
Income Statement
Revenue (ttm) | 76.7M USD |
Revenue Per Share (ttm) | 1.08 USD |
Quarterly Revenue Growth (yoy) | 187.09% |
Gross Profit (ttm) | -250674000 USD |
EBITDA | -345700000 USD |
Net Income Avi to Common (ttm) | -287424000 USD |
Diluted EPS (ttm) | -4.56 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.06B USD |
Total Cash Per Share (mrq) | 14.32 USD |
Total Debt (mrq) | 178.86M USD |
Total Debt/Equity (mrq) | 23.49 USD |
Current Ratio (mrq) | 4.925 |
Book Value Per Share (mrq) | 10.549 |
Cash Flow Statement
Operating Cash Flow (ttm) | -305777984 USD |
Levered Free Cash Flow (ttm) | -174193744 USD |
Profile of Beam Therapeutics
Country | United States |
State | MA |
City | Cambridge |
Address | 238 Main Street |
ZIP | 02142-1016 |
Phone | 857 327 8775 |
Website | https://beamtx.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 523 |
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
Q&A For Beam Therapeutics Stock
What is a current BEAM stock price?
Beam Therapeutics BEAM stock price today per share is 15.27 USD.
How to purchase Beam Therapeutics stock?
You can buy BEAM shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Beam Therapeutics?
The stock symbol or ticker of Beam Therapeutics is BEAM.
Which industry does the Beam Therapeutics company belong to?
The Beam Therapeutics industry is Biotechnology.
How many shares does Beam Therapeutics have in circulation?
The max supply of Beam Therapeutics shares is 99.84M.
What is Beam Therapeutics Price to Earnings Ratio (PE Ratio)?
Beam Therapeutics PE Ratio is now.
What was Beam Therapeutics earnings per share over the trailing 12 months (TTM)?
Beam Therapeutics EPS is -4.58 USD over the trailing 12 months.
Which sector does the Beam Therapeutics company belong to?
The Beam Therapeutics sector is Healthcare.
Beam Therapeutics BEAM included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
Nasdaq US 700 Small Cap Index NQUS700SC | 1938.96 USD — |
-4.51
|
— — | 1891.68 USD — | 1965.66 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2500.59 USD — |
-5.81
|
— — | 2469.29 USD — | 2585.45 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3904.12 USD — |
-5.49
|
— — | 3901.51 USD — | 4064.61 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
NASDAQ Global Select Market Com NQGS | 7625.89 USD — |
-5.84
|
— — | 7621.56 USD — | 7894.21 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}